Innovative Laser and Fiber System for Non Toxic Efficient and Cost Effective Tr...
Innovative Laser and Fiber System for Non Toxic Efficient and Cost Effective Treatment of Cancer
"Our aim with this proposal is to bring the desired technology for a non-toxic, efficient and cost-effective cancer treatment. Basically, all cytotoxic drugs (chemotherapy) and radiation lead to apoptosis, the programmed cell deat...
ver más
31/05/2019
LoF
71K€
Presupuesto del proyecto: 71K€
Líder del proyecto
LABONFIBER GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Fecha límite participación
Sin fecha límite de participación.
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto LUMAX
Duración del proyecto: 6 meses
Fecha Inicio: 2018-11-12
Fecha Fin: 2019-05-31
Líder del proyecto
LABONFIBER GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"Our aim with this proposal is to bring the desired technology for a non-toxic, efficient and cost-effective cancer treatment. Basically, all cytotoxic drugs (chemotherapy) and radiation lead to apoptosis, the programmed cell death of tumor cells. These techniques on the other hand have well documented side effects like losing hair, teeth, damaged quality of life effecting lives of more than 14M cancer patients and their families worldwide. LoF revolutionizes ""non-toxic"" cancer treatment with her innovative laser probes and systems serving oncologists tasked with saving lives by developing and applying the most effective therapies. Our state-of-the-art laser probes and systems form a feedback loop and enable oncologists for the first time to monitor absorbed dose to the tissue in real time which is decisive for the treatment efficacy. Cancer cost the EU €126 billion in 2013, with health care accounting for €51 billion (40% of the total cost) for post-treatments. EU needs better, effective solutions to drive costs down. With our solution which is the subject of this proposal we offer a potential cost-saving of 60%. The market potential for the envisaged the clinical applications is based on current cases at around 2.24 billion euros worldwide. Our innovation opens the door to new treatment applications and could be used to treat up to 5 million people per year from 2022."